Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects

Inclusion Criteria: 1. Healthy Chinese males (age: 18\~45 yrs) with contraception during and 3 months post-dose. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination including blood pressure, pulse, ECG, and laboratory testing. 2. BMI between 19.0 and 28.0 kg/m² and body weight between 55 kg and 80 kg. Exclusion Criteria: 1. suffering from active or latent tuberculosis or history of tuberculosis; 2. have heart disease or a history of heart disease; 3. suffer from mental illness or psychiatric history; 4. suffering from malignant tumors and their history; 5. suffering from herpes zoster and its history; 6. suffering from epilepsy and history of epilepsy; 7. be allergic to the drugs or its components with high sensitivity or allergic reaction, detection of ADA (+); 8. patients who lost blood or donated more than 200 mL within the first 2 months before the screening; 9. major surgery performed within 30 days prior to signing ICF; 10. live vaccine inoculation or vaccination within 12 weeks of screening, or possible administration of vaccine during screening and study visits; 11. previous application of adalimumab or its biosimilars, or anti-TNF alpha drugs; 12. participating in other clinical trials within the first 3 months of the trial; 13. abnormal immune function within 4 weeks before screening; 14. the presence of invasive systemic fungal infection or other opportunistic infections within 2 months prior to screening; 15. systemic or local infection, such as the risk of sepsis and / or known active inflammation within 2 months before screening; 16. 2 months before the screening, there were severe infections in the hospital and / or the need for intravenous antibiotics; 17. 4 or more upper respiratory tract infections occurred within 6 months prior to randomization; 18. hepatitis B surface antigen (HBsAg) positive; if hepatitis B surface antigen (HBsAg) negative, hepatitis B core antibody (HBcAb) positive, peripheral blood hepatitis B virus deoxyribonucleic acid (DNA) test \>0 IU/ml also ruled out; 19. hepatitis C virus (HCV) antibody positive; 20. human immunodeficiency virus (HIV) antibody positive; 21. Treponema pallidum (Treponema pallidum, TP) antibody positive; 22. anti nuclear antibody titer was 1:100 examination; 23. drug abusers, alcohol addicts; 24. , the researchers discretion of failure to follow the requirements of the program, instructions and research limitations, such as uncooperative attitude, unable to return to the Research Center for follow-up visits, or unable to complete the entire clinical study.